Business
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® (dexamethasone intraocular suspension) 9%. Vantage Outsourcing is a leading cataract surgical service provider to a variety of hospitals, ambulatory surgery centers (ASCs), and physicians. The agreement will enable customers in the Vantage Outsourcing network, which spans over a 25+ state service area, to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.\n “We are fortunate to partner with Vantage Outsourcing, as we continue to expand our growing lists of ASCs and integrated healthcare networks in the U.S. that can make DEXYCU available to their cataract surgery patients. Vantage Outsourcing represents a unique opportunity to increase our presence with cataract surgery customers that had previously been beyond our reach, and we believe Vantage Outsourcing is an ideal partner due to our shared commitment to patient care,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “This important partnership aligns with our greater strategic approach of making DEXYCU more widely available to key ASCs and their patients in select U.S. regions.” “We are excited to partner with EyePoint in bringing innovative, high quality products to our surgeons and their patients,” said Ann Deters, Chief Executive Officer of Vantage Outsourcing. “Being able to add DEXYCU to our product service line will allow us to greatly improve the patient’s postoperative experience due to DEXYCU’s long-lasting anti-inflammatory activity and single administration.” About VantageVantage’s business is a shared-surgical service for hospitals, surgery centers and ophthalmologists. Vantage's technical staff bringing equipment, surgical supplies, implants, micro-instruments, as well as technical expertise, to the operating room suite. This innovative model allows facilities to increase surgery revenue, avoid capital equipment risks, increase surgical efficiencies, and convert fixed costs to variable costs, as it relates to surgical procedures. About EyePoint Pharmaceut...